Skip to main content
. 2016 Feb 19;7(13):15828–15839. doi: 10.18632/oncotarget.7489

Figure 2. RUNX1high is associated with poorer outcomes.

Figure 2

(A) OS and (B) EFS in the testing group of 157 CN-AML patients.